title: Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD).
abstract: The Studies of Left Ventricular Dysfunction (SOLVD) trials were designed to evaluate the effects of enalapril on long-term mortality in patients with severe left ventricular (LV) dysfunction. Patients with LV ejection fractions less than or equal to 0.35 and symptoms of congestive heart failure (CHF) were enrolled in the treatment trial, whereas those with no history of overt CHF and taking no treatment directed for LV dysfunction were enrolled in the prevention trial. The baseline clinical characteristics of SOLVD patients were compared to characterize differences between patients in these 2 separate but concurrent trials. From over 70,000 patients screened with LV dysfunction, 4,228 patients were enrolled in the prevention trial and 2,569 patients in the treatment trial. Ischemic heart disease was the primary cause of LV dysfunction in both prevention (83%) and treatment (71%) trial patients. Prior myocardial infarction was present in 80% of the prevention and 66% of the treatment trial patients (p less than 0.001). In the prevention trial, infarction was recent (less than or equal to 6 months) in 27% patients and remote (greater than 6 months) in 57% patients. Treatment trial patients had proportionately more women (20 vs 13%; p less than 0.001) and non-Caucasians (20 vs 14%; p less than 0.001), as well as the coexisting risk factors of hypertension (42 vs 37%; p less than 0.001) and diabetes (26 vs 15%; p less than 0.001) than did prevention trial patients. Clinical characteristics of patients in both trials were influenced by the gender and race of enrolled patients. Similarly, coronary artery bypass surgery was performed less often in women and non-Caucasians.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Epidemiology and Clinical Applications Clinical Trials Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: D
authors.initials: D
authors.lastname: Johnstone
authors.forename: M
authors.initials: M
authors.lastname: Limacher
authors.forename: M
authors.initials: M
authors.lastname: Rousseau
authors.forename: C S
authors.initials: CS
authors.lastname: Liang
authors.forename: L
authors.initials: L
authors.lastname: Ekelund
authors.forename: M
authors.initials: M
authors.lastname: Herman
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: M
authors.initials: M
authors.lastname: Guillotte
authors.forename: G
authors.initials: G
authors.lastname: Bjerken
authors.forename: W
authors.initials: W
authors.lastname: Gaasch
mesh_terms: D000368:Aged; D003327:Coronary Disease / Q000503:physiopathology; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology* / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D044469:Racial Groups; D012307:Risk Factors; D012737:Sex Factors; D013318:Stroke Volume; D016277:Ventricular Function, Left
chemical_list: D004656:Enalapril